Related Experiment Videos
Hepatocellular cholestasis: pathobiology and histological outcome
1Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Seminars in Liver Disease
|November 1, 1995
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Mathematical models of dorsal closure.
Progress in biophysics and molecular biology·2018
Lead Selection and Time of Monitoring in Diagnostic Exercise Testing.
The Physician and sportsmedicine·2016
The plastome of Citrus. Physical map, variation among Citrus cultivars and species and comparison with related genera.
TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres.
Acta biomaterialia·2013
Molecular Mechanisms of Progressive Familial Intrahepatic Cholestasis.
Seminars in liver disease·2026
Metabolic Dysfunction-Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche.
Seminars in liver disease·2026
Advances in Extracorporeal Liver Support.
Seminars in liver disease·2026
Toward Precision Medicine in MASLD: Evolution of Disease Subtyping.
Seminars in liver disease·2026
MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis.
Seminars in liver disease·2026
Endothelial Cell Therapy for the Acute and Chronic Liver Disease.
Seminars in liver disease·2026
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026